A Piece Of The Puzzle Missing From Dr. Hönle AG's (ETR:HNL) Share Price

With a price-to-sales (or "P/S") ratio of 0.6x Dr. Hönle AG (ETR:HNL) may be sending bullish signals at the moment, given that almost half of all the Electrical companies in Germany have P/S ratios greater than 1.5x and even P/S higher than 5x are not unusual. Nonetheless, we'd need to dig a little deeper to determine if there is a rational basis for the reduced P/S.

We've discovered 2 warning signs about Dr. Hönle. View them for free.

Check out our latest analysis for Dr. Hönle

How Dr. Hönle Has Been Performing

Dr. Hönle could be doing better as its revenue has been going backwards lately while most other companies have been seeing positive revenue growth. The P/S ratio is probably low because investors think this poor revenue performance isn't going to get any better. If this is the case, then existing shareholders will probably struggle to get excited about the future direction of the share price.

Want the full picture on analyst estimates for the company? Then our free report on Dr. Hönle will help you uncover what's on the horizon.

Is There Any Revenue Growth Forecasted For Dr. Hönle?

In order to justify its P/S ratio, Dr. Hönle would need to produce sluggish growth that's trailing the industry.

Retrospectively, the last year delivered a frustrating 6.0% decrease to the company's top line. As a result, revenue from three years ago have also fallen 19% overall. So unfortunately, we have to acknowledge that the company has not done a great job of growing revenue over that time.

Turning to the outlook, the next three years should generate growth of 10% per annum as estimated by the dual analysts watching the company. That's shaping up to be similar to the 9.9% each year growth forecast for the broader industry.

With this information, we find it odd that Dr. Hönle is trading at a P/S lower than the industry. Apparently some shareholders are doubtful of the forecasts and have been accepting lower selling prices.

The Final Word

Typically, we'd caution against reading too much into price-to-sales ratios when settling on investment decisions, though it can reveal plenty about what other market participants think about the company.

It looks to us like the P/S figures for Dr. Hönle remain low despite growth that is expected to be in line with other companies in the industry. The low P/S could be an indication that the revenue growth estimates are being questioned by the market. At least the risk of a price drop looks to be subdued, but investors seem to think future revenue could see some volatility.

Don't forget that there may be other risks. For instance, we've identified 2 warning signs for Dr. Hönle (1 makes us a bit uncomfortable) you should be aware of.

If these risks are making you reconsider your opinion on Dr. Hönle, explore our interactive list of high quality stocks to get an idea of what else is out there.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.